Cargando…
Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
Background: Small bowel (SB) lesions in quiescent Crohn’s disease (CD) are sometimes not identified by clinical activity or existing markers. We investigated the usefulness of a novel biomarker, leucine-rich α2-glycoprotein (LRG), for screening for the presence of SB ulcerative lesions detected by s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101788/ https://www.ncbi.nlm.nih.gov/pubmed/35566620 http://dx.doi.org/10.3390/jcm11092494 |
_version_ | 1784707173346967552 |
---|---|
author | Omori, Teppei Sasaki, Yu Koroku, Miki Murasugi, Shun Yonezawa, Maria Nakamura, Shinichi Tokushige, Katsutoshi |
author_facet | Omori, Teppei Sasaki, Yu Koroku, Miki Murasugi, Shun Yonezawa, Maria Nakamura, Shinichi Tokushige, Katsutoshi |
author_sort | Omori, Teppei |
collection | PubMed |
description | Background: Small bowel (SB) lesions in quiescent Crohn’s disease (CD) are sometimes not identified by clinical activity or existing markers. We investigated the usefulness of a novel biomarker, leucine-rich α2-glycoprotein (LRG), for screening for the presence of SB ulcerative lesions detected by small-bowel capsule endoscopy (SBCE). Methods: We examined patients with a Crohn’s Disease Activity Index (CDAI) value < 150 and a C-reactive protein (CRP) value < 0.5 mg/dL with SB or SB colonic CD. The presence of small-bowel ulcerative lesions (≥0.5 cm) was grouped by SBCE results, and we then compared the groups’ LRG value to establish a cutoff value for screening for the presence of lesions. Results: In 40 patients with CD, the LRG values differed significantly between the patients with and without SB ulcerative lesions (Ul + 14.1 (2.1–16.5) μg/mL vs. Ul − 12.3 (9.3–13.5) μg/mL; p = 0.0105). The respective cutoff LRG values for the presence of SB ulcerative lesions was 14 μg/mL (areas under the ROC curve 0.77), with sensitivity 63.6%, specificity 82.8%, positive predictive values 58.3%, negative predictive values 85.7%, and accuracy 78%. Conclusion: These results indicate that LRG may be useful in predicting the presence of SB inflammation associated in patients with CD with CRP < 0.5 mg/dL and CDAI < 150, and in selecting patients for SBCE. |
format | Online Article Text |
id | pubmed-9101788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91017882022-05-14 Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy Omori, Teppei Sasaki, Yu Koroku, Miki Murasugi, Shun Yonezawa, Maria Nakamura, Shinichi Tokushige, Katsutoshi J Clin Med Article Background: Small bowel (SB) lesions in quiescent Crohn’s disease (CD) are sometimes not identified by clinical activity or existing markers. We investigated the usefulness of a novel biomarker, leucine-rich α2-glycoprotein (LRG), for screening for the presence of SB ulcerative lesions detected by small-bowel capsule endoscopy (SBCE). Methods: We examined patients with a Crohn’s Disease Activity Index (CDAI) value < 150 and a C-reactive protein (CRP) value < 0.5 mg/dL with SB or SB colonic CD. The presence of small-bowel ulcerative lesions (≥0.5 cm) was grouped by SBCE results, and we then compared the groups’ LRG value to establish a cutoff value for screening for the presence of lesions. Results: In 40 patients with CD, the LRG values differed significantly between the patients with and without SB ulcerative lesions (Ul + 14.1 (2.1–16.5) μg/mL vs. Ul − 12.3 (9.3–13.5) μg/mL; p = 0.0105). The respective cutoff LRG values for the presence of SB ulcerative lesions was 14 μg/mL (areas under the ROC curve 0.77), with sensitivity 63.6%, specificity 82.8%, positive predictive values 58.3%, negative predictive values 85.7%, and accuracy 78%. Conclusion: These results indicate that LRG may be useful in predicting the presence of SB inflammation associated in patients with CD with CRP < 0.5 mg/dL and CDAI < 150, and in selecting patients for SBCE. MDPI 2022-04-29 /pmc/articles/PMC9101788/ /pubmed/35566620 http://dx.doi.org/10.3390/jcm11092494 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Omori, Teppei Sasaki, Yu Koroku, Miki Murasugi, Shun Yonezawa, Maria Nakamura, Shinichi Tokushige, Katsutoshi Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy |
title | Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy |
title_full | Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy |
title_fullStr | Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy |
title_full_unstemmed | Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy |
title_short | Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy |
title_sort | serum leucine-rich alpha-2 glycoprotein in quiescent crohn’s disease as a potential surrogate marker for small-bowel ulceration detected by capsule endoscopy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101788/ https://www.ncbi.nlm.nih.gov/pubmed/35566620 http://dx.doi.org/10.3390/jcm11092494 |
work_keys_str_mv | AT omoriteppei serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy AT sasakiyu serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy AT korokumiki serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy AT murasugishun serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy AT yonezawamaria serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy AT nakamurashinichi serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy AT tokushigekatsutoshi serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy |